PreMD to Present Data on New LungAlert(TM) Test Format at American Association for Clinical Chemistry Meeting
April 10 2006 - 10:00AM
PR Newswire (US)
TORONTO, April 10 /PRNewswire-FirstCall/ -- Predictive medicine
company PreMD Inc. (TSX: PMD; Amex: PME) today announced that a
scientific abstract describing a new microwell-based format of
LungAlert(TM) has been accepted for presentation at the upcoming
American Association for Clinical Chemistry Annual Meeting, July 23
- 27, 2006, in Chicago, Illinois. "This new, patent-pending test
format can be processed using standard, automated equipment that is
found in many laboratories," said Dr. Brent Norton, President and
Chief Executive Officer. "We believe the microwell-based format
will enhance the value of our cancer portfolio to potential
partners and help to create additional market opportunities for
these tests." The abstract accepted for presentation is A
Microwell-Based Galactose Oxidase-Schiff's Assay for
Thomsen-Friedenreich Antigen in Diagnosis of Lung Cancer, by G. Cox
and J. Miller, of McMaster University, Hamilton, Ontario, and R.
Zawydiwski, M. Evelegh and C. Carte, of PreMD. The AACC is an
international scientific/medical society of clinical laboratory
professionals, physicians, research scientists and others involved
with clinical laboratory medicine, science and related disciplines.
The AACC provides leadership in advancing the practice and
profession of clinical laboratory medicine and its role in
improving health care. Its members develop and perform tests
conducted in hospital laboratories, clinics, medical centers and
other health care settings. About PreMD PreMD Inc. is a world
leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products, which are branded as
PREVU(x) Skin Sterol Test, are licensed worldwide to McNeil
Consumer Healthcare. The company's cancer tests include
ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's
head office is located in Toronto, and its research and product
development facility is at McMaster University in Hamilton,
Ontario. For further information, please visit
http://www.premdinc.com/. For more information about PREVU(x),
please visit http://www.prevu.com/ or call 1-866-283-8328 (North
America) or 00-800-8283-8328 (Europe), or email . This press
release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could
cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties
include, among others, the successful development or marketing of
the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating
profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies,
product liability, reliance on third-party manufacturers, the
ability of the Company to take advantage of business opportunities,
uncertainties related to the regulatory process, and general
changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the
protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain
patent protection for our products or product candidates. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. PreMD is providing this information as
of the date of this press release and does not undertake any
obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or
otherwise. For more information, please contact: Sarah Borg-Olivier
Director, Communications Tel: 416-222-3449 ext. 27 Email:
DATASOURCE: PreMD Inc. CONTACT: Sarah Borg-Olivier, Director,
Communications, Tel: (416) 222-3449 ext. 27, Email:
Copyright